Bladder Cancer
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.
January 8, 2025
The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary
January 7, 2025
Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer.
January 7, 2025
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials.
January 3, 2025
Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.
January 2, 2025
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer.
January 1, 2025
Does time matter in early radical cystectomy? Comparing outcome, clinical and pathological characteristics of immediate versus deferred radical cystectomy.
December 31, 2024
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
December 31, 2024
The Financial Burden of Localized and Metastatic Bladder Cancer.
December 30, 2024
Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis.
December 30, 2024